马拉维生命科学 MRVI
$7.52 +$0.54 (+7.74%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $7.67 +1.99%
开盘$7.02
昨收$6.98
当日区间$7.01 – $7.62
成交量1.94M
市值$1.12B
市盈率（TTM）–
股息率–
财报
财报日平均波动±15.5%近16次财报
收涨次数7 / 1644% 的概率
最佳反应+63.6%
最差反应-35.3%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 6 Aug 2026 | After Market | ±27.4% | -0.32% | 符合区间 |
| 2026/Q1 | 7 May 2026 | After Market | – | +23.10% | – |
| 2025/Q4 | 25 Feb 2026 | After Market | ±25.7% | +9.20% | 符合区间 |
| 2025/Q3 | 6 Nov 2025 | After Market | – | -0.69% | – |
| 2025/Q2 | 11 Aug 2025 | After Market | ±24.5% | +30.58% | 超出定价预期 |
| 2025/Q1 | 12 May 2025 | After Market | ±25.5% | -2.83% | 符合区间 |
| 2024/Q4 | 18 Mar 2025 | After Market | ±19.4% | -5.81% | 符合区间 |
| 2024/Q3 | 7 Nov 2024 | After Market | ±31.2% | -35.27% | 超出定价预期 |
| 2024/Q2 | 7 Aug 2024 | After Market | ±13.9% | -6.87% | 符合区间 |
| 2024/Q1 | 8 May 2024 | After Market | ±25.4% | +11.16% | 符合区间 |
| 2023/Q4 | 22 Feb 2024 | After Market | ±23.9% | +63.60% | 超出定价预期 |
| 2023/Q3 | 7 Nov 2023 | After Market | ±20.3% | -31.69% | 超出定价预期 |
| 2023/Q2 | 7 Aug 2023 | After Market | ±30.5% | +0.73% | 符合区间 |
| 2023/Q1 | 8 May 2023 | After Market | ±28.0% | -13.02% | 符合区间 |
| 2022/Q4 | 22 Feb 2023 | After Market | ±17.7% | +8.17% | 符合区间 |
| 2022/Q3 | 2 Nov 2022 | After Market | ±16.6% | -5.53% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2026/Q2 季度
按业务线
基本面
最新报告季度：Q2, ended Jun 2026
营收$51.44M+8.5% YoY
营业利润-$15.12M+57.8% YoY
净利润-$21.63M+69.0% YoY
摊薄每股收益-$0.08+70.4% YoY
自由现金流$3.62M+127.6% YoY
经营现金流$3.99M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率34.9%
营业利润率-33.7%
净利率-37.1%
净资产收益率-32.9%
资产收益率-10.3%
投入资本回报率-12.2%
流动比率4.05
负债/资产比率41.1%
现金及投资$70.09M
总负债$176.70M
净现金（净负债）-$106.61M
暂无评论——快来第一个聊聊 MRVI。
登录后参与讨论。